Maplight Therapeutics, Inc. (MPLT) Stock Price & Analysis
Maplight Therapeutics, Inc. (MPLT) fell 0.64% to USD 29.27 as of June 10, 2026 at 04:05 UTC, according to Nexqual real-time market data.
MPLT last closed at USD 29.46; the session ranged USD 28.14–30.6 on volume of 251,124 shares. Market capitalization is $1.33B, with a 52-week range of USD 12.24–33.28 (NMS). Source: Nexqual, June 10, 2026 at 04:05 UTC.
Key Statistics (as of June 10, 2026 at 04:05 UTC)
| Price | USD 29.27 |
|---|---|
| Change | ▼ 0.64% (down) |
| Previous Close | USD 29.46 |
| Open | USD 29.83 |
| Day Range | USD 28.14 – 30.6 |
| 52-Week Range | USD 12.24 – 33.28 |
| Volume | 251,124 shares |
| Market Cap | $1.33B |
| Exchange | NMS |
Technical Analysis (MPLT)
Nexqual's technical model rates MPLT "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 04:05 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 52.62 (neutral) |
| vs SMA50 | Above (USD 27.76) |
| MACD | 0.33 (positive) |
Analyst Ratings (MPLT)
Wall Street analysts rate MPLT "Strong Buy" based on 10 analysts, with a mean price target of USD 38.7 (range USD 30–48), per Nexqual as of June 10, 2026 at 04:05 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 38.7 |
| High Target | USD 48 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (MPLT)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -1.42 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.34 vs est -1.09 ▼ miss |
| 2025-12-31 | USD -2.47 vs est -0.83 ▼ miss |
| 2025-09-30 | USD -37.18 vs est -1.73 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:05 UTC.
Financials & Fundamentals (MPLT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -80.95% |
| Debt / Equity | 1.4 |
| Current Ratio | 22.91 |
| Total Cash | $310.11M |
| Total Debt | $5.59M |
| Free Cash Flow | $-95.70M |
Source: Nexqual, June 10, 2026 at 04:05 UTC.
Financial Health Score (MPLT)
Nexqual rates Maplight Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $310M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$164M |
| Efficiency | Critical — ROE -81%, ROA -49.5% |
Ownership (MPLT)
| Insider Ownership | +51.16% |
|---|---|
| Institutional Ownership | +55.97% |
| Shares Outstanding | 42.62M |
| Float | 13.40M |
| Short % of Float | +7.10% |
Source: Nexqual, June 10, 2026 at 04:05 UTC.
Leadership (MPLT)
Maplight Therapeutics, Inc. is led by Christopher A. Kroeger M.B.A. (age 57), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 04:05 UTC.
| Founder, President, CEO & Director | Christopher A. Kroeger M.B.A. (age 57) |
|---|---|
| Co-Founder, Member of Scientific Advisory Board & Director | Robert C. Malenka (age 69) |
| Chief Financial Officer | Vishwas Setia (age 37) |
| Chief Scientific Officer | James Woodruff Lillie (age 69) |
Major Backers & Investors (MPLT)
Notable institutional backers of Maplight Therapeutics, Inc. include T. Rowe Price, Novo Holdings A/S, FCPM III Services B.V., according to Nexqual as of June 10, 2026 at 04:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 10.3% |
| Novo Holdings A/S | 8.65% |
| FCPM III Services B.V. | 7.57% |
| Goldman Sachs | 4.68% |
| Blue Owl Capital Holdings LP | 2.36% |
| Nan Fung Group Holdings Limited | 2.28% |
| 5AM Venture Management, LLC | 2.23% |
| Sanofi | 2.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.2% |
| Vanguard Group | 3.34% |
Source: Nexqual, June 10, 2026 at 04:05 UTC.
From Maplight Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
- The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LBRX | LB Pharmaceuticals Inc | USD 29.27 | ▲ 2.59% |
| EVMN | Evommune, Inc. | USD 20.49 | ▲ 2.86% |
| MAZE | Maze Therapeutics, Inc. | USD 23.93 | ▼ 1.4% |
| UPB | Upstream Bio, Inc. | USD 6.69 | ▼ 5.11% |
| SION | Sionna Therapeutics, Inc. | USD 33.69 | ▼ 4.75% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:05 UTC. This page is informational and not investment advice.